Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-10T09:26:49.311Z Has data issue: false hasContentIssue false

Ciprofloxacin-induced acute psychosis in a patient with multidrug-resistant tuberculosis

Published online by Cambridge University Press:  16 April 2020

Christine Norra*
Affiliation:
Department of Psychiatry and Psychotherapy, University Aachen, Pauwelsstrasse 30, Aachen52074, Germany
Erik Skobel
Affiliation:
Department of Internal Medicine, University Aachen, Pauwelsstrasse 30, Aachen52074, Germany
Christian Breuer
Affiliation:
Department of Internal Medicine, University Aachen, Pauwelsstrasse 30, Aachen52074, Germany
Gerhard Haase
Affiliation:
Institute of Medical Microbiology, University Aachen, Pauwelsstrasse 30, Aachen52074, Germany
Peter Hanrath
Affiliation:
Department of Internal Medicine, University Aachen, Pauwelsstrasse 30, Aachen52074, Germany
Paul Hoff
Affiliation:
Department of Psychiatry and Psychotherapy, University Aachen, Pauwelsstrasse 30, Aachen52074, Germany
*
2Corresponding author. cnorra@ukaachen.de
Get access

Abstract

Tuberculosis (TB) increasingly appears in a multidrug-resistant form (MDR-TB) in Europe, too. Treatment remains difficult due to various side effects of the multi-drug-regimens. Ciprofloxacin is widely used as one of the few TB-second-line drugs. We report on the course of a ciprofloxacin-induced acute psychosis in a patient with MDR(isoniazid, streptomycin)-TB which resolved after cessation of ciprofloxacin treatment and introduction of a novel oxazolidone. Careful treatment considerations particularly in patients with additional predisposing factors to neuropsychiatric symptoms are recommended in the potentially dangerous MDR-TB, thus creating an enormous therapeutic challenge.

Type
Case report
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Also, AO, Yolles, JC.Isoniazid-induced psychosis. Ann Pharmaco-therapy 1998;32:889–90.Google Scholar
Bifani, PJ, Mathema, B, Kurepina, NE, Kreiswirth, BN.Global dissemination of Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002;10:45–52.CrossRefGoogle ScholarPubMed
Farrington, J, Stoudemire, A, Tierney, J.The role of ciprofloxacin in a patient with delirium due to multiple etiologies. Gen Hosp Psychiatry 1995;17:47–53.CrossRefGoogle Scholar
Hollweg, M, Kapfhammer, HP, Krupinski, M, Moller, HJ.Psychopatho-logical syndromes in treatment with gyrase inhibitors. Nervenarzt 1997;68:38–47.CrossRefGoogle ScholarPubMed
Iseman, MD. Treatment of multidrug-resistant tuberculosis. N Eng J Med 1993;329:784–91.Google ScholarPubMed
James, EA, Demian, AZ.Acute psychosis in a trauma patient due to ciprofloxacin. Postgrad Med J 1998;74:189–90.CrossRefGoogle Scholar
Robert-Koch-Institut. Epidemiologisches Bulletin Nr. 11, 15.3.2002.Google Scholar
Unseld, E, Zeilger, G, Gemeinhardt, A, Janssen, U, Kotz, U.Possible interaction of fluoroquinolones with the benzodiazepine–GABA A-receptor complex. Br J Clin Pharmacol 1990;30:63–70.CrossRefGoogle Scholar
Yew, WW, Chan, CK, Chau, CH, Tam, CM, Leung, CC, Wong, PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744–51.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.